New drug BL-B01D1 targets Hard-to-Treat solid tumors in early trial

NCT ID NCT05785039

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase II trial is testing a drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The study aims to find the best dose and see how well the drug shrinks tumors, while also monitoring safety and side effects. Participants receive the drug by IV infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced urinary system or other solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early Phase II trial with only 76 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm neoplasm prostate cancer urinary system neoplasm urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR URINARY SYSTEM TUMOR

Contacts and locations

Locations

Fudan University ShangHai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.